Berberine vs BPC-157
Both are used for gut health. Here's how they compare on human evidence, mechanism, safety and availability — in plain English.
| Berberine | BPC-157 | |
|---|---|---|
| Human evidence | ★★★★☆ | ★★★☆☆ |
| Legal status | OTC Supplement | Not Approved |
| How it works | Activates AMPK by the same energy-sensor route as metformin. The AMPK switch → the AMPK pathway. Downstream: lowers hepatic glucose output, improves insulin sensitivity, shifts fuel toward fat oxidation, and reshapes gut microbiota. Its… | A 15-amino-acid fragment of a gastric protein. Two characterised pathways: (1) upregulates VEGFR2 (KDR) → PI3K/Akt → eNOS (NOS3), driving angiogenesis (new blood vessels to injured tissue); (2) a Src–Caveolin-1–eNOS route. It also… |
| In plain English | "Nature's metformin" — it flips the same low-fuel switch (AMPK). Best for pre-diabetes and high triglycerides. Poorly absorbed, so split the dose with meals or use dihydroberberine. | It tells injured tissue to grow a fresh blood supply (via the VEGFR2 switch), and blood flow is what healing runs on — so tendons, ligaments, gut lining and muscle appear to mend faster. The catch: almost all the evidence is in rats. Human… |
| Bottom line | Strong metabolic supplement; pair with glucose monitoring. | The most promising healing peptide by animal data — and the biggest human-evidence gap. Watch the July 2026 PCAC decision. |
| Availability | Available over the counter | Not widely approved |
Which is better for gut health?
Berberine has the stronger human-evidence rating (★★★★☆ vs ★★★☆☆), but the right choice still depends on your goal, tolerance and budget.
Common questions
Is Berberine or BPC-157 better for gut health?
Berberine has the stronger human-evidence rating (★★★★☆ vs ★★★☆☆), but the right choice still depends on your goal, tolerance and budget.
What's the difference between Berberine and BPC-157?
Berberine: Strong metabolic supplement; pair with glucose monitoring. — BPC-157: The most promising healing peptide by animal data — and the biggest human-evidence gap. Watch the July 2026 PCAC decision.